Loading...
XNAS
SLS
Market cap2.38bUSD
Jul 10, Last price  
12.76USD
1D
-5.55%
1Q
168.07%
IPO
-96.73%
Name

Sellas Life Sciences Group Inc

Chart & Performance

D1W1MN
XNAS:SLS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
68.72%
Rev. gr., 5y
0.00%
Revenues
0k
0000002,038,0002,487,0009,319,000000001,900,0007,600,0001,000,000000
Net income
-27m
L-13.01%
-2,405,000-10,990,000-14,373,000-18,387,000-11,993,000-11,485,000-34,969,000-76,678,000-36,606,000-63,902,000-23,549,000-23,754,000-27,670,000-19,292,000-16,757,000-20,699,000-41,301,000-37,340,000-30,881,000-26,863,000
CFO
-28m
L-19.81%
-2,112,000-6,047,000-9,429,000-11,769,000-10,257,000-14,668,000-20,963,000-28,908,000-42,869,000-48,160,000-44,915,000-10,989,000-30,422,000-17,643,000-10,417,000-26,021,000-23,809,000-31,410,000-35,402,000-28,389,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
URL
https://www.sellaslifesciences.com/
IPO date
Mar 12, 2008
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT